Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Olmesartan versus Candesartan on Fasting Glucose Impairment in Hypertensive Patients Receiving Statin Therapy
KCT0005143Phase 4Recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Jun 2020
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of olmesartan and candesartan in hypertension (HTN) and hyperlipidemia (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoint: Change in fasting glucose. Started Jun 2020; status: recruiting.
02
Drugs
olmesartancandesartan
03
Conditions
hypertension (HTN)hyperlipidemia
Beyond the preview
Go deeper on KCT0005143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005143.